FDA staff finds no new safety problems with Glaxo's asthma drug
March 17, 2015 at 09:32 AM EDT
March 17 (Reuters) - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found.